Antioxidant enzyme Prdx1 inhibits osteoclastogenesis via suppressing ROS and NFATc1 signaling pathways
Journal of Cellular Physiology · 2024
DOI: 10.1002/jcp.31431 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2024. Verfasst von Chao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Discipline of Pathology and Laboratory, School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Osteoclasts, Reactive Oxygen Species, Signal Transduction, Osteogenesis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bone is a dynamic organ which continuously undergoes remodeling throughout one's lifetime. Cellular production of reactive oxygen species (ROS) is essential for regulating bone homeostasis. Osteoclasts, multinucleated giant cells differentiated from macrophage lineage, are responsible for osteolytic bone conditions which are closely linked to ROS signaling pathways. In this study, an anti‐ROS enzyme, peroxiredoxin 1 (Prdx1) was found to be expressed both in bone marrow macrophages and osteoclasts. Recombinant Prdx1 protein was found to dose‐dependently inhibit ROS production and osteoclast differentiation. Mechanistically, Prdx1 protein also attenuated NFATc1 activation as well as the expression of C‐Fos, V‐ATPase‐d2, Cathepsin K, and Integrin αV. Collectively, Prdx1 is a negative regulator on osteoclast formation via inhibiting RANKL‐mediated ROS activity, thus suggesting its potential application for treating osteoclast related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Discipline of Pathology and Laboratory, School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia.
- Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
- Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Zitieren
APA
Wang, C., Wang, G., Song, F., Zhao, J., Liu, Q., & Xu, J. (2024). Antioxidant enzyme Prdx1 inhibits osteoclastogenesis via suppressing ROS and NFATc1 signaling pathways. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31431
Vancouver
Wang C, Wang G, Song F, Zhao J, Liu Q, Xu J. Antioxidant enzyme Prdx1 inhibits osteoclastogenesis via suppressing ROS and NFATc1 signaling pathways. Journal of Cellular Physiology. 2024. doi:10.1002/jcp.31431
BibTeX
@article{Wang2024,
author = {Wang, Chao and Wang, Gang and Song, Fangming and Zhao, Jinmin and Liu, Qian and Xu, Jiake},
title = {Antioxidant enzyme Prdx1 inhibits osteoclastogenesis via suppressing ROS and NFATc1 signaling pathways},
journal = {Journal of Cellular Physiology},
year = {2024},
doi = {10.1002/jcp.31431}
}
EUVIMED